Clinical Trial Update: Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and tolerability of BCX9930 in complement-mediated kidney diseases was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complement Glomerulopathy
• Immunoglobulin Nephropathy
• Membranous Nephropathy

Drugs mentioned

• BCX9930 (Factor D inhibitor)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2024-05-02